Market Cap 9.26B
Revenue (ttm) 675.04M
Net Income (ttm) 141.21M
EPS (ttm) N/A
PE Ratio 99.01
Forward PE 97.62
Profit Margin 20.92%
Debt to Equity Ratio 0.00
Volume 1,029,100
Avg Vol 814,876
Day's Range N/A - N/A
Shares Out 105.19M
Stochastic %K 93%
Beta 0.20
Analysts Sell
Price Target $135.25

Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also develop...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 327 3270
Address:
101 Redwood Shores Parkway, Redwood City, United States
gucag006
gucag006 Dec. 14 at 4:55 AM
$CORT Final countdown to the Relacorilant-4-Cushing PDUFA date - 10 workdays to 12/30/25. Relacorilant is a much better med for Cushing than Korlym (mifepristone) or the so-called abortion pill. Korlym was the first drug from CORT, which enjoyed great commercial success with 2024 sales of $675M and growing. Mifepristone adheres to 3 receptors including the one causes abortion with the following side effects: "The most common side effects of Korlym (mifepristone) include nausea, fatigue, headache, low blood potassium, joint pain, and swelling of the extremities. Serious side effects, such as pregnancy loss, adrenal insufficiency, and heart rhythm problems, can also occur." Relacorilant, on the other hand, adheres to the GR receptor only (as glucocorticoid receptor antagonist) which regulates cortisol - a much safer dtug and can be subscribed to the entire population, male or female. It should be a smooth sailing thru FDA, and billion $$ revenue per year is just around the corner.
0 · Reply
voorbie
voorbie Dec. 13 at 3:42 AM
$CORT We haven’t heard from @stewpackard here in a while. It must be killing them not to post smug comments.
0 · Reply
gucag006
gucag006 Dec. 13 at 3:33 AM
$LXRX $CORT Sharing these comments with my CORT Long friends.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 12 at 11:36 PM
0 · Reply
steven_targets
steven_targets Dec. 12 at 2:01 PM
$CORT specialty pharma, highly focused on a narrow indication with strong cash generation
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 12 at 12:54 PM
2 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:48 PM
Actionable Trade Alert for $CORT: Market Context: $CORT is currently trading at $86.6, showing strong momentum but is overbought with an RSI of 79.5. The stock is above its 30-day (MA30) and 50-day (MA50) moving averages, indicating a bullish trend. However, caution is warranted due to the high RSI, suggesting potential for a pullback. Directional Bias: The recent high of $91.0 indicates resistance, while the low of $67.0 provides a support range. Given the current price, there is potential for a short-term pullback before a continuation upward. Trade Plan: - Suggested Entry: $86.6 - Stop Loss: $83.6 (3% below entry) - Take Profit Targets: 1. $90.0 (+3.9% ROI) 2. $92.5 (+6.9% ROI) 3. $101.0 (+16.5% ROI) With these targets, the third take profit aligns with a potential 17% ROI or more. Monitor the price action closely, especially around the resistance level at $91.0. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
MrMaglue
MrMaglue Dec. 11 at 9:21 PM
$CORT Interesting action 12/11, 15:11 - 1517est ;0)
1 · Reply
Daniech0514
Daniech0514 Dec. 10 at 5:28 AM
$CORT I think there is greater than 50% chance this gets BO before July pdufa if it passes this December pdufa. What are your opinions?
4 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:52 AM
Actionable Trade Alert for $CORT: Market Context: $CORT is currently trading at $83.15, showing strong momentum but is in overbought territory with an RSI of 72.14. The stock has recently approached the 60D high of $91.00, indicating potential resistance. Directional Bias: The high RSI suggests a pullback may occur, but the price is above both the 30-day MA (77.31) and 50-day MA (78.31), indicating bullish momentum. The recent high-low range (60D High: $91.00, Low: $67.00) supports potential upward movement but requires caution. Trade Plan: - Suggested Entry: $83.15 - Stop Loss: $79.00 (approximately 5% below entry) - Take Profit Targets: 1. Target 1: $87.00 (4.5% ROI) 2. Target 2: $90.00 (8.3% ROI) 3. Target 3: $97.00 (16.7% ROI) With a target of $97.00, this trade offers a potential ROI of 16.7%, aligning with our goal of 17% or more. Monitor for volatility given the ATR of 3.07. https://privateprofiteers.com
0 · Reply
Latest News on CORT
Corcept Transition To New Specialty Pharmacy Well Underway

Oct 15, 2025, 9:13 AM EDT - 2 months ago

Corcept Transition To New Specialty Pharmacy Well Underway


Corcept Primed For An Upside EPS Surprise

Sep 26, 2025, 12:06 PM EDT - 2 months ago

Corcept Primed For An Upside EPS Surprise


gucag006
gucag006 Dec. 14 at 4:55 AM
$CORT Final countdown to the Relacorilant-4-Cushing PDUFA date - 10 workdays to 12/30/25. Relacorilant is a much better med for Cushing than Korlym (mifepristone) or the so-called abortion pill. Korlym was the first drug from CORT, which enjoyed great commercial success with 2024 sales of $675M and growing. Mifepristone adheres to 3 receptors including the one causes abortion with the following side effects: "The most common side effects of Korlym (mifepristone) include nausea, fatigue, headache, low blood potassium, joint pain, and swelling of the extremities. Serious side effects, such as pregnancy loss, adrenal insufficiency, and heart rhythm problems, can also occur." Relacorilant, on the other hand, adheres to the GR receptor only (as glucocorticoid receptor antagonist) which regulates cortisol - a much safer dtug and can be subscribed to the entire population, male or female. It should be a smooth sailing thru FDA, and billion $$ revenue per year is just around the corner.
0 · Reply
voorbie
voorbie Dec. 13 at 3:42 AM
$CORT We haven’t heard from @stewpackard here in a while. It must be killing them not to post smug comments.
0 · Reply
gucag006
gucag006 Dec. 13 at 3:33 AM
$LXRX $CORT Sharing these comments with my CORT Long friends.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 12 at 11:36 PM
0 · Reply
steven_targets
steven_targets Dec. 12 at 2:01 PM
$CORT specialty pharma, highly focused on a narrow indication with strong cash generation
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 12 at 12:54 PM
2 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:48 PM
Actionable Trade Alert for $CORT: Market Context: $CORT is currently trading at $86.6, showing strong momentum but is overbought with an RSI of 79.5. The stock is above its 30-day (MA30) and 50-day (MA50) moving averages, indicating a bullish trend. However, caution is warranted due to the high RSI, suggesting potential for a pullback. Directional Bias: The recent high of $91.0 indicates resistance, while the low of $67.0 provides a support range. Given the current price, there is potential for a short-term pullback before a continuation upward. Trade Plan: - Suggested Entry: $86.6 - Stop Loss: $83.6 (3% below entry) - Take Profit Targets: 1. $90.0 (+3.9% ROI) 2. $92.5 (+6.9% ROI) 3. $101.0 (+16.5% ROI) With these targets, the third take profit aligns with a potential 17% ROI or more. Monitor the price action closely, especially around the resistance level at $91.0. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
MrMaglue
MrMaglue Dec. 11 at 9:21 PM
$CORT Interesting action 12/11, 15:11 - 1517est ;0)
1 · Reply
Daniech0514
Daniech0514 Dec. 10 at 5:28 AM
$CORT I think there is greater than 50% chance this gets BO before July pdufa if it passes this December pdufa. What are your opinions?
4 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:52 AM
Actionable Trade Alert for $CORT: Market Context: $CORT is currently trading at $83.15, showing strong momentum but is in overbought territory with an RSI of 72.14. The stock has recently approached the 60D high of $91.00, indicating potential resistance. Directional Bias: The high RSI suggests a pullback may occur, but the price is above both the 30-day MA (77.31) and 50-day MA (78.31), indicating bullish momentum. The recent high-low range (60D High: $91.00, Low: $67.00) supports potential upward movement but requires caution. Trade Plan: - Suggested Entry: $83.15 - Stop Loss: $79.00 (approximately 5% below entry) - Take Profit Targets: 1. Target 1: $87.00 (4.5% ROI) 2. Target 2: $90.00 (8.3% ROI) 3. Target 3: $97.00 (16.7% ROI) With a target of $97.00, this trade offers a potential ROI of 16.7%, aligning with our goal of 17% or more. Monitor for volatility given the ATR of 3.07. https://privateprofiteers.com
0 · Reply
moorenard1
moorenard1 Dec. 10 at 1:29 AM
$CORT In the run from $75 in mid Nov to the mid $80S everyone assumed this was the shorts covering ahead of PDUFA date. Turns out they weren't. They were digging themselves into an even deeper hole. Shorts sold another 175k shares ($15 million) in the last 2 weeks! Instead of being in the hole $500 million if they had prudently closed out half their position, the short position is now hovering around 1 BILLION DOLLARS. They need to buy 1 billion worth of stock at today's price. However, as soon as they start covering, the price (and their liability) will rapidly increase. Their total liability is going to be closer to 4 billion if they are lucky. Even worse (for them), the days to cover ballooned from 14 to almost 20. This means it would take 20 days of shorts aggressively buying the entire volume of stock every day for 20 consecutive days to cover their 1 billilon short position. Only the math doesn't check out. There are only 13 trading days left between now and PDUFA.
4 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 9 at 11:10 PM
0 · Reply
Social_Idiot
Social_Idiot Dec. 9 at 10:50 PM
$CORT Oh come on!!!!! These AHs are killing me!
0 · Reply
Social_Idiot
Social_Idiot Dec. 9 at 1:55 PM
$CORT Show us the AH excitement from yesterday during regular hours today!
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 9 at 11:26 AM
$CORT The indication is non-oncology (endocrinologic), which tends to have higher approval rates than oncology. • The NDA submission was based on multiple trials (pivotal Phase 3 + long-term extension + Phase 2) with reportedly good safety/tolerability.  • The disease (hypercortisolism / Cushing’s) is serious with unmet needs, which might encourage regulatory flexibility. • My estimate: **~ 70–80% probability of approval**. • I lean toward the high side because of favorable indication type + robust clinical data + orphan-disease context.
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 9 at 2:18 AM
$CORT wow this is chaotic !
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:40 PM
Actionable Trade Alert for $CORT: Market Context: $CORT is currently trading at $84.5, showing strength as it approaches the 60D high of $91.0. The RSI is at 78.46, indicating overbought conditions, suggesting potential price pullbacks. However, the strong momentum could push the price higher. Directional Bias: Given the recent close above the MA30 (77.0) and MA50 (78.35), the trend remains bullish. The proximity to the 60D high indicates a possible breakout, but caution is warranted due to the high RSI. Trade Plan: - Suggested Entry: $84.5 - Stop Loss: $81.5 (3.5% below entry) - Take Profit Targets: 1. $88.0 (4.2% gain) 2. $90.0 (6.5% gain) 3. $99.0 (17.1% gain) This trade plan offers a favorable risk-reward ratio, with the potential for a significant ROI on the third target. Monitor RSI for signs of reversal before entering. https://privateprofiteers.com
0 · Reply
NAZCORP
NAZCORP Dec. 8 at 10:28 PM
$CORT Big Spike in AH to $90 on some systems.
1 · Reply
druvaciam
druvaciam Dec. 8 at 9:14 PM
$CORT Not a great day for CORT.
1 · Reply
Social_Idiot
Social_Idiot Dec. 8 at 8:56 PM
$CORT Why is this pulling back so hard?
0 · Reply
moorenard1
moorenard1 Dec. 8 at 6:14 PM
$CORT MOTHER OF ALL SHORT SQUEEZES Shorts only have 15 trading days until PDUFA. No way they can buy-back the 10 million shares they need to in that timeframe. If Relacorilant gets approved, watch out for the mother of all short squeezes.....math suggests stock will go above $200/sh I'm buying more here. Get your popcorn ready.....
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 8 at 1:54 PM
Our earlier post compared $NBIX Crenessity product revenue post FDA approval/launch to peers acquired in that $10B range like Verona & Immunogen suggesting, but not confirming, NBIX's Crenessity might be worthj a similar number in a M&A exit. Here we show valuation & revenue projection data for the 10 commercial-stage non-oncology focused peers with market caps ranging from $6 to $15B. NBIX's Ingrezza is a powerhouse by itself on track to doing $2.5B in FY25. This is not investment advice but we really like NBIX. $RYTM has a great drug with multiple catalysts nearing including a PDUFA & a P3 read. Still RYTM trades at a very high multiple of analyst revenue estimates compared to these peers. $CORT Relacorilant has an upcoming PDUFA in Cushing's followed by ovarian cancer. We considered CORT non-oncology but that will change if approved. $BMRN is a great company but to us appears a textbook example of the risks of staying independent. BMRN is down ~50% from Xmas 2015. $IONS was the same ?
2 · Reply